Kenneth Simon

Kenneth Simon is a Senior Director at Syngene International Limited, specializing in Integrated Drug Discovery since July 2023. With extensive experience as a consultant in biologics therapeutic development, protein engineering, and molecular biology since 2016, Kenneth has contributed to therapeutic antibody development and supported Crispr gene therapy vector design at Editas Medicine. Previous roles include Senior Director at Revitope Oncology, focusing on T-cell engaging Antibody Circuits, and Director of Biology at Tilos Therapeutics, overseeing immuno-oncology models. Kenneth also served as Director of Molecular Biology and Virology at Oncorus, Project Director at AbbVie for bispecific antibody therapeutics, and Associate Director at Biogen, where significant contributions to PML risk mitigation and antibody development were made. Early career positions included postdoctoral research at The Salk Institute and graduate research at ARIAD Pharmaceuticals and Cold Spring Harbor Laboratory. Kenneth holds a PhD in Molecular and Cellular Biology from Stony Brook University and a Bachelor of Arts in Biochemistry and Cell Biology from UC San Diego.